Neuvasq’s lead molecule NVQ401 is a highly potent Wnt surrogate antibody that is being developed as an investigational treatment for vascular retinopathies, such as diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).
Neuvasq is working on a second, preclinical program focused on Wnt surrogate antibodies for neurological diseases.
NVQ401, specifically designed for retinal diseases
NVQ401 is designed to treat retinopathies that are associated with dysfunction and leakiness of the blood-retina barrier and abnormal neovascularization.
Diabetic Macular Edema (DME) – one of the most widespread causes of blindness
DME is a complication of diabetes that impacts more than 20 million people worldwide. In DME, excess fluid accumulates in the retina, resulting from damage to the BRB.
Wet Age Related Macular Degeneration (wAMD) – most common cause of vision impairment in aging patients
wAMD is the most common complication of age-related macular degeneration, which is characterized by choroidal neovascularization with leaky blood vessels. It affects more than 20 million patients worldwide.
Cookie policy